TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06487455: An Open, Multicenter, Dose-escalation, and Dose-expansion Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of SPH7485 Tablets in Patients With Advanced Solid Tumors.

Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 170 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06487455 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06487455 Rescue Dossier →